Atara Biotherapeutics is Biotechnology in United States that focus on Atara Biotherapeutics Inc business. Founded in 2012. They cover business area such as Atara Biotherapeutics Inc, patient, cancer, autoimmune and other viral disease, two group, product candidate, derive antigen-specific T-cell, molecularly target biologic.
2012
( 12 years old in 2024 )
Atara Biotherapeutics Inc
-
611 Gateway Boulevard
Suite 900
South San Francisco, CA 94080
United States
Private
Atara Biotherapeutics Incpatientcancerautoimmune and other viral diseasetwo groupproduct candidatederive antigen-specific T-cellmolecularly target biologic
* We use standard office opening hours in near Atara Biotherapeutics's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Atara Biotherapeutics is Biotechnology business from United States that founded in 2012 (12 years old in 2024), Atara Biotherapeutics business is focusing on Atara Biotherapeutics Inc.
Atara Biotherapeutics headquarter office and corporate office address is located in 611 Gateway Boulevard Suite 900 South San Francisco, CA 94080 United States.
Atara Biotherapeutics was founded in United States.
In 2024, Atara Biotherapeutics is currently focus on Atara Biotherapeutics Inc sector.
Above is snippet of Google Trends for "Atara Biotherapeutics Inc" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Atara Biotherapeutics, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
